This topic contains a solution. Click here to go to the answer

Author Question: The second process in Mowrer's two-process theory of avoidance involves _____ in the form of _____. ... (Read 151 times)

Anajune7

  • Hero Member
  • *****
  • Posts: 574
The second process in Mowrer's two-process theory of avoidance involves _____ in the form of _____.
 
  A) negative punishment; fear induction
  B) negative reinforcement; fear reduction
  C) negative reinforcement; shock removal
  D) negative punishment; shock presentation

Question 2

The second process in Mowrer's two-process theory of avoidance involves:
 
  A) classical conditioning of a fear response.
  B) classical conditioning of an approach response.
  C) negative punishment resulting from the reduction of fear.
  D) negative reinforcement resulting from the reduction of fear.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

bblaney

  • Sr. Member
  • ****
  • Posts: 323
Answer to Question 1

B

Answer to Question 2

D




Anajune7

  • Member
  • Posts: 574
Reply 2 on: Jun 21, 2018
:D TYSM


Dominic

  • Member
  • Posts: 328
Reply 3 on: Yesterday
Great answer, keep it coming :)

 

Did you know?

Chronic necrotizing aspergillosis has a slowly progressive process that, unlike invasive aspergillosis, does not spread to other organ systems or the blood vessels. It most often affects middle-aged and elderly individuals, spreading to surrounding tissue in the lungs. The disease often does not respond to conventionally successful treatments, and requires individualized therapies in order to keep it from becoming life-threatening.

Did you know?

Immunoglobulin injections may give short-term protection against, or reduce severity of certain diseases. They help people who have an inherited problem making their own antibodies, or those who are having certain types of cancer treatments.

Did you know?

Lower drug doses for elderly patients should be used first, with titrations of the dose as tolerated to prevent unwanted drug-related pharmacodynamic effects.

Did you know?

According to the CDC, approximately 31.7% of the U.S. population has high low-density lipoprotein (LDL) or "bad cholesterol" levels.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library